Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs12998806
rs12998806
G 0.710 GeneticVariation GWASCAT In addition, we confirmed SNP rs10069690 was the best indicator for ER-negative breast cancer at 5p15.33 (OR = 1.30; P = 2.4 × 10 − 10) and identified rs12998806 as the best indicator for ER-positive breast cancer at 2q35 (OR = 1.34; P = 2.2 × 10 − 8) for women of African ancestry. 28171663

2016

dbSNP: rs12998806
rs12998806
0.710 GeneticVariation BEFREE In addition, we confirmed SNP rs10069690 was the best indicator for ER-negative breast cancer at 5p15.33 (OR = 1.30; P = 2.4 × 10 − 10) and identified rs12998806 as the best indicator for ER-positive breast cancer at 2q35 (OR = 1.34; P = 2.2 × 10 − 8) for women of African ancestry. 28171663

2016

dbSNP: rs11251942
rs11251942
0.700 GeneticVariation GWASCAT Genome-wide association study of germline variants and breast cancer-specific mortality. 30787463

2019

dbSNP: rs12938141
rs12938141
0.700 GeneticVariation GWASCAT Genome-wide association study of germline variants and breast cancer-specific mortality. 30787463

2019

dbSNP: rs140538758
rs140538758
0.700 GeneticVariation GWASCAT Genome-wide association study of germline variants and breast cancer-specific mortality. 30787463

2019

dbSNP: rs4717568
rs4717568
0.700 GeneticVariation GWASCAT Genome-wide association study of germline variants and breast cancer-specific mortality. 30787463

2019

dbSNP: rs587150
rs587150
0.700 GeneticVariation GWASCAT Genome-wide association study of germline variants and breast cancer-specific mortality. 30787463

2019

dbSNP: rs62235635
rs62235635
0.700 GeneticVariation GWASCAT Genome-wide association study of germline variants and breast cancer-specific mortality. 30787463

2019

dbSNP: rs6938753
rs6938753
0.700 GeneticVariation GWASCAT Genome-wide association study of germline variants and breast cancer-specific mortality. 30787463

2019

dbSNP: rs7082321
rs7082321
0.700 GeneticVariation GWASCAT Genome-wide association study of germline variants and breast cancer-specific mortality. 30787463

2019

dbSNP: rs73370840
rs73370840
0.700 GeneticVariation GWASCAT Genome-wide association study of germline variants and breast cancer-specific mortality. 30787463

2019

dbSNP: rs79116769
rs79116769
0.700 GeneticVariation GWASCAT Genome-wide association study of germline variants and breast cancer-specific mortality. 30787463

2019

dbSNP: rs12586722
rs12586722
A 0.700 GeneticVariation GWASCAT SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway. 28429243

2017

dbSNP: rs2981579
rs2981579
T 0.700 GeneticVariation GWASCAT Genome-Wide Testing of Exonic Variants and Breast Cancer Risk in the California Teachers Study. 28864454

2017

dbSNP: rs10941679
rs10941679
0.020 GeneticVariation BEFREE Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. 27640304

2016

dbSNP: rs700518
rs700518
0.020 GeneticVariation BEFREE Because AI use results in severe estrogen deficiency that may lead to changes in body composition, the aim of this study was to determine the effect of the rs700518 polymorphism in the CYP19A1 gene on the changes in body composition among postmenopausal women who were treated with AIs for ER+ breast cancer. 26049585

2015

dbSNP: rs865686
rs865686
0.020 GeneticVariation BEFREE We recently identified a novel susceptibility variant, rs865686, for estrogen-receptor positive breast cancer at 9q31.2. 25652398

2015

dbSNP: rs10941679
rs10941679
0.020 GeneticVariation BEFREE In addition, we find both rs4415084 and rs10941679 conferred significantly greater risks of ER-positive breast cancer than of ER-negative tumors. 24039999

2013

dbSNP: rs700518
rs700518
0.020 GeneticVariation BEFREE Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer. 23643682

2013

dbSNP: rs865686
rs865686
0.020 GeneticVariation BEFREE 9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium. 22859399

2012

dbSNP: rs17822931
rs17822931
0.010 GeneticVariation BEFREE Our data showed that a significant association between rs17822931 and the risk of breast cancer, especially ER-positive breast cancer, in Japanese women. 30883634

2019

dbSNP: rs192876988
rs192876988
0.010 GeneticVariation BEFREE In follow-up studies of the 10 identified variants, the GK2 region SNP, rs192876988, showed an inverse association with EOC in European ancestry women (p = 0.002), increased risk of ER positive breast cancer in African ancestry women (p = 0.027) and decreased expression of GK2 in HGSOC tissue from African ancestry women (p = 0.004). 31469419

2019

dbSNP: rs4442975
rs4442975
0.010 GeneticVariation BEFREE SNP rs4442975 was associated with a greater reduction of risk of ER-positive breast cancer [odds ratio (OR)int = 0.85 (0.78-0.93), Pint = 2.8 x 10-4] and overall breast cancer [ORint = 0.85 (0.78-0.92), Pint = 7.4 x 10-5) in current users of estrogen-progesterone therapy compared with non-users. 31605532

2019

dbSNP: rs13689
rs13689
0.010 GeneticVariation BEFREE The C allele of <i>CDH1</i>:rs13689 (odds ratio [OR], 2.121; <i>p</i>=0.033) was found to be associated with ER-positive breast cancer. 29963112

2018

dbSNP: rs992531
rs992531
0.010 GeneticVariation BEFREE We identified a novel locus (rs992531 at 8p21.2) associated with reduced survival among the patients with ER-positive breast cancer (<i>P =</i> 3.77 × 10<sup>-8</sup>). 29423119

2018